Amyloid-Beta Vaccine; Paradoxical Kinesia in Parkinson’s; Genetic Migraine Risks

An investigational Alzheimer’s vaccine safely generated immunity to pyroglutamate amyloid-beta in animal studies. (Brain Communications)

Eli Lilly delayed its timeline to apply for accelerated approval for donanemab, its investigational Alzheimer’s drug, after CMS proposed restricting coverage of amyloid-targeting drugs to people in clinical trials. (Fierce Biotech)

Meanwhile, the Securities and Exchange Commission and Federal Trade Commission opened two more investigations into the approval and marketing of Biogen’s Alzheimer’s drug aducanumab (Aduhelm). (Fierce Pharma)

Why can some people with Parkinson’s disease suddenly move quickly and fluidly? Researchers discuss their search for the biological underpinnings of paradoxical kinesia. (NPR)

Neuromodulation showed promise in treating functional neurological disorder, especially transcranial magnetic stimulation for functional motor symptoms. (Journal of Neurology, Neurosurgery & Psychiatry)

Answer ALS, a new online resource, offers population-level biological and clinical data to help identify new amyotrophic lateral sclerosis subtypes. (Nature Neuroscience)

Risk of acute ischemic stroke in people 65 and older rose the first 3 days after COVID-19 diagnosis. (Neurology)

A genome-wide analysis of more than 100,000 migraine cases identified 123 loci connected to migraine risk, most of which were previously unknown. (Nature Genetics)

People who had less memory loss as they aged gained more knowledge. (Science Advances)

The FDA placed a full clinical hold on atuzaginstat (COR388), an investigational oral therapy for Alzheimer’s disease that targets gingipains, Cortexyme said.

The dorsal precentral gyrus plays a key role in how people use their voice to control how they want words to sound, cortical recordings showed. (PLOS Biology)

Baclofen oral suspension (Fleqsuvy) was approved to treat spasticity in people with multiple sclerosis (MS) or spinal cord injuries and other spinal cord diseases, Azurity Pharmaceuticals announced.

At 1 year postpartum, about 10% of women with MS had significant relapse-related disability from stopping natalizumab (Tysabri) during pregnancy. (JAMA Network Open)